Literature DB >> 20664358

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

Dongxia Xing1, Alan G Ramsay, John G Gribben, William K Decker, Jared K Burks, Mark Munsell, Sufang Li, Simon N Robinson, Hong Yang, David Steiner, Nina Shah, John D McMannis, Richard E Champlin, Chitra Hosing, Patrick A Zweidler-McKay, Elizabeth J Shpall, Catherine M Bollard.   

Abstract

Peripheral blood natural killer (NK) cell therapy for acute myeloid leukemia has shown promise in clinical trials after allogeneic stem cell transplantation. Cord blood (CB) is another potentially rich source of NK cells for adoptive immune therapy after stem cell transplantation. Tightly regulated receptor signaling between NK cells and susceptible tumor cells is essential for NK cell-mediated cytotoxicity. However, despite expressing normal surface activating and inhibitory NK receptors, CB-derived NK cells have poor cytolytic activity. In this study, we investigate the cellular mechanism and demonstrate that unmanipulated CB-NK cells exhibit an impaired ability to form F-actin immunologic synapses with target leukemia cells compared with peripheral blood-derived NK cells. In addition, there was reduced recruitment of the activating receptor CD2, integrin leukocyte function-associated antigen-1, and the cytolytic molecule perforin to the CB-NK synapse site. Exvivo interleukin (IL)-2 expansion of CB-NK cells enhanced lytic synapse formation including CD2 and leukocyte function-associated antigen-1 polarization and activity. Furthermore, the acquired antileukemic function of IL-2-expanded CB-NK cells was validated using a nonobese diabetic severe combined immunodeficient IL-2 receptor common γ-chain null mouse model. We believe our results provide important mechanistic insights for the potential use of IL-2-expanded CB-derived NK cells for adoptive immune therapy in leukemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20664358      PMCID: PMC3530422          DOI: 10.1097/CJI.0b013e3181e475e9

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  34 in total

1.  Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity.

Authors:  Xi Chen; Prachi P Trivedi; Baoxue Ge; Konrad Krzewski; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-29       Impact factor: 11.205

2.  A dual role for talin in NK cell cytotoxicity: activation of LFA-1-mediated cell adhesion and polarization of NK cells.

Authors:  Emily M Mace; Susan J Monkley; David R Critchley; Fumio Takei
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

3.  Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.

Authors:  U Koehl; R Esser; S Zimmermann; T Tonn; R Kotchetkov; T Bartling; J Sörensen; H-P Grüttner; P Bader; E Seifried; H Martin; P Lang; J R Passweg; T Klingebiel; D Schwabe
Journal:  Klin Padiatr       Date:  2005 Nov-Dec       Impact factor: 1.349

4.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

Review 5.  Formation and function of the lytic NK-cell immunological synapse.

Authors:  Jordan S Orange
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

6.  HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.

Authors:  Esther Morel; Teresa Bellón
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 7.  The killer's kiss: the many functions of NK cell immunological synapses.

Authors:  Konrad Krzewski; Jack L Strominger
Journal:  Curr Opin Cell Biol       Date:  2008-07-17       Impact factor: 8.382

Review 8.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

9.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

Authors:  Alan G Ramsay; Amy J Johnson; Abigail M Lee; Güllü Gorgün; Rifca Le Dieu; William Blum; John C Byrd; John G Gribben
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

10.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.

Authors:  R Willemze; C A Rodrigues; M Labopin; G Sanz; G Michel; G Socié; B Rio; A Sirvent; M Renaud; L Madero; M Mohty; C Ferra; F Garnier; P Loiseau; J Garcia; L Lecchi; G Kögler; Y Beguin; C Navarrete; T Devos; I Ionescu; K Boudjedir; A-L Herr; E Gluckman; V Rocha
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more
  22 in total

Review 1.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 2.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

Review 3.  Umbilical cord blood graft engineering: challenges and opportunities.

Authors:  P A Thompson; K Rezvani; C M Hosing; B Oran; A L Olson; U R Popat; A M Alousi; N D Shah; S Parmar; C Bollard; P Hanley; P Kebriaei; L Cooper; J Kellner; I K McNiece; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Zoledronate increases enrichment, activation and expansion of natural killer cells from umbilical cord blood.

Authors:  Zhijie Ma; Yunhong Wang; Huiyan Kang; Xiaoyun Wu
Journal:  Hum Cell       Date:  2018-06-13       Impact factor: 4.174

5.  A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

Authors:  Sumithira Vasu; Maria Berg; Jan Davidson-Moncada; Xin Tian; Herb Cullis; Richard W Childs
Journal:  Cytotherapy       Date:  2015-11       Impact factor: 5.414

Review 6.  Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Authors:  Patrick J Hanley; Conrad Russell Cruz; Elizabeth J Shpall; Catherine M Bollard
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

7.  Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture.

Authors:  Suzanne L Tomchuck; Wing H Leung; Mari H Dallas
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-18       Impact factor: 5.742

Review 8.  Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.

Authors:  M S Cairo; N Tarek; D A Lee; C Delaney
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 9.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

Review 10.  Cord blood graft engineering.

Authors:  Colleen Delaney; Catherine M Bollard; Elizabeth J Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-17       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.